

Marc de Garidel

CEO, Abivax

Marc de Garidel is a recognized biotech entrepreneur and global pharmaceutical executive with a distinguished track record of building and scaling innovative healthcare companies, advancing breakthrough therapies, and creating substantial shareholder value across the biotechnology sector. Since May 2023, Marc has served as Chief Executive Officer of Abivax, leading the development of obefazimod for ulcerative colitis and driving exceptional corporate growth, from a \$500M to up to \$14B company in over 3 years. Prior to Abivax, he was Chief Executive Officer of CinCor Pharma from 2020 to 2023, where he successfully led the company through its acquisition by AstraZeneca. CinCor's lead therapy was subsequently approved by the FDA as a first-in-class treatment for resistant hypertension. From 2018 to 2020, Marc served as CEO of Corvidia Therapeutics, overseeing its strategic growth and successful acquisition by Novo Nordisk. Earlier in his career, he served as Chief Executive Officer of Ipsen from 2010 to 2016, where he transformed the company into a leading global oncology player through the expansion of Somatuline and the landmark ex-U.S. licensing agreement for Cabometyx. Marc began his career at Eli Lilly and Company before spending 15 years at Amgen in senior international leadership roles. He has also served as Chairman of Ipsen since late 2010. He holds a Civil Engineering degree from ESTP Paris, a Master's in International Management from Thunderbird School of Global Management, and an Executive MBA from Harvard Business School.